Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.

Fouad T Chebib,Xiaolei Zhou,Diana Garbinsky,Eric Davenport,Sasikiran Nunna,Dorothee Oberdhan,Ancilla Fernandes

Kidney medicine（2023）

引用 1|浏览15

暂无评分

摘要

TEMPO 2:4 (NCT00413777); phase 1 tolvaptan trial (no NCT number; trial number 156-06-260); phase 2 tolvaptan trial (NCT01336972); TEMPO 4:4 (NCT01214421); REPRISE (NCT02160145); long-term tolvaptan safety extension trial (NCT02251275); OVERTURE (NCT01430494); HALT Progression of Polycystic Kidney Disease (HALT-PKD) study B (NCT01885559).

查看译文

关键词

Autosomal dominant polycystic kidney disease (ADPKD),clinical trial,glomerular filtration rate (GFR),subgroup analysis,tolvaptan

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要